Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 1
2006 3
2007 2
2009 5
2010 5
2011 3
2012 2
2013 3
2015 2
2017 3
2018 3
2019 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Toxicities of Histone Deacetylase Inhibitors.
Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Subramanian S, et al. Among authors: piekarz rl. Pharmaceuticals (Basel). 2010 Aug 26;3(9):2751-2767. doi: 10.3390/ph3092751. Pharmaceuticals (Basel). 2010. PMID: 27713375 Free PMC article. Review.
Challenges of evaluating the cardiac effects of anticancer agents.
Bates SE, Rosing DR, Fojo T, Piekarz RL. Bates SE, et al. Among authors: piekarz rl. Clin Cancer Res. 2006 Jul 1;12(13):3871-4. doi: 10.1158/1078-0432.CCR-06-1017. Clin Cancer Res. 2006. PMID: 16818679 Review. No abstract available.
Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections.
Kim J, Singh H, Ayalew K, Borror K, Campbell M, Johnson LL, Karesh A, Khin NA, Less JR, Menikoff J, Minasian L, Mitchell SA, Papadopoulos EJ, Piekarz RL, Prohaska KA, Thompson S, Sridhara R, Pazdur R, Kluetz PG. Kim J, et al. Among authors: piekarz rl. Clin Cancer Res. 2018 Apr 15;24(8):1780-1784. doi: 10.1158/1078-0432.CCR-17-2555. Epub 2017 Dec 13. Clin Cancer Res. 2018. PMID: 29237718 Review.
E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group.
Connolly RM, Zhao F, Miller KD, Lee MJ, Piekarz RL, Smith KL, Brown-Glaberman UA, Winn JS, Faller BA, Onitilo AA, Burkard ME, Budd GT, Levine EG, Royce ME, Kaufman PA, Thomas A, Trepel JB, Wolff AC, Sparano JA. Connolly RM, et al. Among authors: piekarz rl. J Clin Oncol. 2021 Oct 1;39(28):3171-3181. doi: 10.1200/JCO.21.00944. Epub 2021 Aug 6. J Clin Oncol. 2021. PMID: 34357781 Free PMC article. Clinical Trial.
Impact of ABCB1 allelic variants on QTc interval prolongation.
Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, Franke R, Clark JA, Miller-DeGraff L, Steinberg SM, Venzon D, Liewehr D, Kleeberger SR, Bates SE, Price DK, Rosing DR, Cabell C, Sparreboom A, Figg WD. Sissung TM, et al. Among authors: piekarz rl. Clin Cancer Res. 2011 Feb 15;17(4):937-46. doi: 10.1158/1078-0432.CCR-10-0925. Epub 2010 Nov 24. Clin Cancer Res. 2011. PMID: 21106724 Free PMC article.
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. Coyne GO', et al. Among authors: piekarz rl. Cancer Chemother Pharmacol. 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. Cancer Chemother Pharmacol. 2020. PMID: 32314030 Free PMC article. Clinical Trial.
34 results